Designing the Foundation: Optimizing First-Line Therapy for EGFR-Mutated Advanced NSCLC

Please visit answersincme.com/860/103117485-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prof. Solange Peters, MD, PhD; and Pasi A. Jänne, MD, PhD. In this activity, experts in EGFR-mutated advanced non–small-cell lung cancer (NSCLC) discuss practical strategies for optimizing first-line testing and treatment selection. Upon completion of this series, participants should be better able to: Interpret updated evidence and recommendations regarding first-line testing and treatment selection for patients with advanced EGFR-mutated NSCLC; and Discuss the role of emerging therapies in advanced EGFR-mutated NSCLC, applying insights from tumor biology to optimize sequential treatment decisions.